Learning Objectives

Upon completion of this activity, the learner should be able to:

· Compare the relative advantages and timing of different endoleak therapies

· Assess current data for evaluation of upper GI bleeding treated by embolization

· Explain the role and benefit of various embolic material for GI bleeding embolization

· Determine interventional oncologic therapy decisions based on the latest evidence, established patient care standards and multidisciplinary approaches

· Describe the latest imaging techniques that may help in performing intra-arterial treatment of liver cancer.

· Compare the latest options and differences in function, characteristics and potential outcomes of various devices for embolization.

· Discuss the new therapeutic options using embolization in hemorrhoid-related bleeding,

· Analyze the potential indication of embolization in various joint disorders (frozen shoulder, knee osteoarthritis, tennis elbow, enthesopathy)

· Discuss basic and variant prostate artery anatomy and techniques to identify critical vasculature during therapy.

· Assess patient symptoms and treatment options for symptomatic benign prostatic hyperplasia, including drug treatment, surgery, and embolization.

· Assess the indication and results for PAE in BPH

· Determine the potential role of bariatric embolization

· Explain the indications and results of uterine fibroid and adenomyosis embolization.

· Summarize the advantages, limitations, technical aspects, and endpoints of various tools and approaches to visceral aneurysm treatment.

· Synthesize the results and indication for liver mets of MRCC intra-arterial treatment including Y 90, DEBIRI, Intra-arterial ports

· Determine the respective role of DEB and conventional TACE in HCC

· Identify the potential role for resorbable particles

· Restate technique, indication and results of lung and liver tumor ablation

Target Audience

GEST 2018 U.S. will be of value to interventional radiologists, oncologists, diagnostic radiologists, nurses, radiology technologists, physician assistants, and other healthcare professionals interested in the field of embolization.

CME Accreditation Statement

Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement

Complete Conference Management designates this live activity for a maximum of 26 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credits

 ANCC

For the purpose of recertification, American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

AANP

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

ARRT

Association for Vascular and Interventional Radiographers (AVIR) ARRT Accreditation. Approved by the AVIR for 25.5 Category A+ CEs

ABR

American Board of Radiology (ABR) Self - Assessments (SAMs). This program is approved for a maximum of 10.75 self-assessment credits (SAM) by Complete Conference Management. Complete Conference Management is awarded Deemed Status by the American Board of Radiology (ABR). The SAMs offered at this live meeting, meet the ABR’s criteria for a self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification (MOC) Program. Attendees may take a self-assessment test at the time of certificate retrieval. Look for the MOC symbol next to program listings.

ABS

American Board of Surgery (ABS) Maintenance of Certification (MOC) Part 2. Attendees may take a self-assessment test at the time of certificate retrieval. Achieving a score of 75% or more on unlimited attempts will allow the AMA PRA Category 1 Credits™ earned at GEST to count towards the self-assessment credits required by Part 2 of the ABS MOC Program. Look for the MOC symbol next to program listings.

AVIR

Association for Vascular and Interventional Radiographers (AVIR) ACE Accreditation. This program is approved by the Association for Vascular and Interventional Radiographers (AVIR) for a total of 52.75 Category A+ CE (maximum of 26)

UEMS/EACCME CME Credit Recognition

The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Disclaimer

Complete Conference Management makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Complete Conference Management must demonstrate balance, independence, objectivity, and scientific rigor.  All faculty, authors, editors, and planning committee members participating in an CCM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure of Unlabeled Use

Complete Conference Management requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.